Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA

J. A. Bell, Elena Volpi, S. Fujita, J. G. Cadenas, Blake Rasmussen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aims/hypothesis: An elevated lipid content within skeletal muscle cells is associated with the development of insulin resistance and type 2 diabetes mellitus. We hypothesised that in subjects with type 2 diabetes muscle malonyl-CoA (an inhibitor of fatty acid oxidation) would be elevated at baseline in comparison with control subjects and in particular during physiological hyperinsulinaemia with hyperglycaemia. Thus, fatty acids taken up by muscle would be shunted away from oxidation and towards storage (non-oxidative disposal). Materials and methods: Six control subjects and six subjects with type 2 diabetes were studied after an overnight fast and during a hyperinsulinaemic (0.5 mU kg-1 min-1), hyperglycaemic clamp (with concurrent intra-lipid and heparin infusions) designed to increase muscle malonyl-CoA and inhibit fat oxidation. We used stable isotope methods, femoral arterial and venous catheterisation, and performed muscle biopsies to measure palmitate kinetics across the leg and muscle malonyl-CoA. Results: Basal muscle malonyl-CoA concentrations were similar in control and type 2 diabetic subjects and increased (p<0.05) in both groups during the clamp (control, 0.14± 0.05 to 0.24±0.05 pmol/mg; type 2 diabetes, 0.09±0.01 to 0.20±0.02 pmol/mg). Basal palmitate oxidation across the leg was not different between groups at baseline and decreased in both groups during the clamp (p<0.05). Palmitate uptake and non-oxidative disposal were significantly greater in the type 2 diabetic subjects at baseline and during the clamp (p<0.05). Conclusions/interpretation: Contrary to our hypothesis, the dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of muscle malonyl-CoA. However, elevated fatty acid uptake in type 2 diabetes may be a key contributing factor to the increase in fatty acids being shunted towards storage within muscle.

Original languageEnglish (US)
Pages (from-to)2144-2152
Number of pages9
JournalDiabetologia
Volume49
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Malonyl Coenzyme A
Type 2 Diabetes Mellitus
Fatty Acids
Muscles
Palmitates
Leg
Lipids
Hyperinsulinism
Thigh
Catheterization
Isotopes
Hyperglycemia
Muscle Cells
Insulin Resistance
Heparin
Skeletal Muscle
Fats
Biopsy

Keywords

  • Fatty acid uptake
  • Malonyl-CoA
  • Muscle fatty acid oxidation
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA. / Bell, J. A.; Volpi, Elena; Fujita, S.; Cadenas, J. G.; Rasmussen, Blake.

In: Diabetologia, Vol. 49, No. 9, 09.2006, p. 2144-2152.

Research output: Contribution to journalArticle

@article{c7a37df378574899b8ed19a253fe3f06,
title = "Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA",
abstract = "Aims/hypothesis: An elevated lipid content within skeletal muscle cells is associated with the development of insulin resistance and type 2 diabetes mellitus. We hypothesised that in subjects with type 2 diabetes muscle malonyl-CoA (an inhibitor of fatty acid oxidation) would be elevated at baseline in comparison with control subjects and in particular during physiological hyperinsulinaemia with hyperglycaemia. Thus, fatty acids taken up by muscle would be shunted away from oxidation and towards storage (non-oxidative disposal). Materials and methods: Six control subjects and six subjects with type 2 diabetes were studied after an overnight fast and during a hyperinsulinaemic (0.5 mU kg-1 min-1), hyperglycaemic clamp (with concurrent intra-lipid and heparin infusions) designed to increase muscle malonyl-CoA and inhibit fat oxidation. We used stable isotope methods, femoral arterial and venous catheterisation, and performed muscle biopsies to measure palmitate kinetics across the leg and muscle malonyl-CoA. Results: Basal muscle malonyl-CoA concentrations were similar in control and type 2 diabetic subjects and increased (p<0.05) in both groups during the clamp (control, 0.14± 0.05 to 0.24±0.05 pmol/mg; type 2 diabetes, 0.09±0.01 to 0.20±0.02 pmol/mg). Basal palmitate oxidation across the leg was not different between groups at baseline and decreased in both groups during the clamp (p<0.05). Palmitate uptake and non-oxidative disposal were significantly greater in the type 2 diabetic subjects at baseline and during the clamp (p<0.05). Conclusions/interpretation: Contrary to our hypothesis, the dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of muscle malonyl-CoA. However, elevated fatty acid uptake in type 2 diabetes may be a key contributing factor to the increase in fatty acids being shunted towards storage within muscle.",
keywords = "Fatty acid uptake, Malonyl-CoA, Muscle fatty acid oxidation, Type 2 diabetes",
author = "Bell, {J. A.} and Elena Volpi and S. Fujita and Cadenas, {J. G.} and Blake Rasmussen",
year = "2006",
month = "9",
doi = "10.1007/s00125-006-0362-9",
language = "English (US)",
volume = "49",
pages = "2144--2152",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA

AU - Bell, J. A.

AU - Volpi, Elena

AU - Fujita, S.

AU - Cadenas, J. G.

AU - Rasmussen, Blake

PY - 2006/9

Y1 - 2006/9

N2 - Aims/hypothesis: An elevated lipid content within skeletal muscle cells is associated with the development of insulin resistance and type 2 diabetes mellitus. We hypothesised that in subjects with type 2 diabetes muscle malonyl-CoA (an inhibitor of fatty acid oxidation) would be elevated at baseline in comparison with control subjects and in particular during physiological hyperinsulinaemia with hyperglycaemia. Thus, fatty acids taken up by muscle would be shunted away from oxidation and towards storage (non-oxidative disposal). Materials and methods: Six control subjects and six subjects with type 2 diabetes were studied after an overnight fast and during a hyperinsulinaemic (0.5 mU kg-1 min-1), hyperglycaemic clamp (with concurrent intra-lipid and heparin infusions) designed to increase muscle malonyl-CoA and inhibit fat oxidation. We used stable isotope methods, femoral arterial and venous catheterisation, and performed muscle biopsies to measure palmitate kinetics across the leg and muscle malonyl-CoA. Results: Basal muscle malonyl-CoA concentrations were similar in control and type 2 diabetic subjects and increased (p<0.05) in both groups during the clamp (control, 0.14± 0.05 to 0.24±0.05 pmol/mg; type 2 diabetes, 0.09±0.01 to 0.20±0.02 pmol/mg). Basal palmitate oxidation across the leg was not different between groups at baseline and decreased in both groups during the clamp (p<0.05). Palmitate uptake and non-oxidative disposal were significantly greater in the type 2 diabetic subjects at baseline and during the clamp (p<0.05). Conclusions/interpretation: Contrary to our hypothesis, the dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of muscle malonyl-CoA. However, elevated fatty acid uptake in type 2 diabetes may be a key contributing factor to the increase in fatty acids being shunted towards storage within muscle.

AB - Aims/hypothesis: An elevated lipid content within skeletal muscle cells is associated with the development of insulin resistance and type 2 diabetes mellitus. We hypothesised that in subjects with type 2 diabetes muscle malonyl-CoA (an inhibitor of fatty acid oxidation) would be elevated at baseline in comparison with control subjects and in particular during physiological hyperinsulinaemia with hyperglycaemia. Thus, fatty acids taken up by muscle would be shunted away from oxidation and towards storage (non-oxidative disposal). Materials and methods: Six control subjects and six subjects with type 2 diabetes were studied after an overnight fast and during a hyperinsulinaemic (0.5 mU kg-1 min-1), hyperglycaemic clamp (with concurrent intra-lipid and heparin infusions) designed to increase muscle malonyl-CoA and inhibit fat oxidation. We used stable isotope methods, femoral arterial and venous catheterisation, and performed muscle biopsies to measure palmitate kinetics across the leg and muscle malonyl-CoA. Results: Basal muscle malonyl-CoA concentrations were similar in control and type 2 diabetic subjects and increased (p<0.05) in both groups during the clamp (control, 0.14± 0.05 to 0.24±0.05 pmol/mg; type 2 diabetes, 0.09±0.01 to 0.20±0.02 pmol/mg). Basal palmitate oxidation across the leg was not different between groups at baseline and decreased in both groups during the clamp (p<0.05). Palmitate uptake and non-oxidative disposal were significantly greater in the type 2 diabetic subjects at baseline and during the clamp (p<0.05). Conclusions/interpretation: Contrary to our hypothesis, the dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of muscle malonyl-CoA. However, elevated fatty acid uptake in type 2 diabetes may be a key contributing factor to the increase in fatty acids being shunted towards storage within muscle.

KW - Fatty acid uptake

KW - Malonyl-CoA

KW - Muscle fatty acid oxidation

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33746670639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746670639&partnerID=8YFLogxK

U2 - 10.1007/s00125-006-0362-9

DO - 10.1007/s00125-006-0362-9

M3 - Article

C2 - 16868746

AN - SCOPUS:33746670639

VL - 49

SP - 2144

EP - 2152

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 9

ER -